284,430 Shares in Damora Therapeutics, Inc. Common Stock $DMRA Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 284,430 shares of the company’s stock, valued at approximately $7,398,000. Damora Therapeutics, Inc. Common Stock makes up 1.2% of Seven Fleet Capital Management LP’s holdings, making the stock its 18th largest holding. Seven Fleet Capital Management LP owned 0.46% of Damora Therapeutics, Inc. Common Stock as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Braidwell LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth about $42,146,000. Sigma Planning Corp purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $334,000. Ikarian Capital LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $6,574,000. Jain Global LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at approximately $2,774,000. Finally, Remedium Capital Partners LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $2,772,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ DMRA opened at $30.06 on Friday. The company has a market capitalization of $1.86 billion, a P/E ratio of -8.92 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a one year low of $2.45 and a one year high of $38.33. The stock has a 50 day moving average price of $29.74 and a 200-day moving average price of $26.89.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.06. As a group, equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DMRA shares. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 target price for the company. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wedbush increased their price objective on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $44.00.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.